


## What is EMBRACE?

EMBRACE is a pioneering embryonic cell-free DNA test developed by Igenomix that allows your clinic to identify the embryos that are the most likely to be chromosomally normal without a biopsy.

This information helps patients and physicians decide which embryo to prioritize and transfer first in an IVF cycle, maximizing the chance of a healthy pregnancy.

## Test Results

Embryos most likely to be chromosomally normal will be given the highest score and prioritized for transfer.



## How does it work?



Embryos stay safely  
in the IVF clinic



## Who is it for?

EMBRACE is for patients undergoing IVF who wish to transfer embryos most likely to be chromosomally normal.

Patients requiring PGT-M or PGT-SR should pursue testing based on trophectoderm biopsy.



## EMBRACE IS BASED ON THE FOLLOWING DATA:

# A multicenter prospective study on the concordance between embryonic cell-free DNA and trophectoderm biopsies from 1,301 human blastocysts


The recent identification of embryonic cell-free DNA in the spent blastocyst media has opened a new era of possibilities for embryonic aneuploidy testing in assisted reproductive technologies.

1

During development, embryonic cell-free DNA is released into the culture medium with increasing concentration as the number of cells multiplies from day 4 to day 6.

2

The spent culture medium containing embryonic cell-free DNA is analyzed by next generation sequencing (NGS). The chromosome copy number of the blastocyst is assessed without the need for trophectoderm biopsy.



v1.2020

### 3

Igenomix has carried out a study in eight IVF centers comparing the results obtained in embryonic cell-free DNA from 1,301 spent blastocyst media and the corresponding trophectoderm biopsies in couples undergoing preimplantation genetic testing for aneuploidy (PGT-A).







# 1,301

Spent blastocyst media

This is the largest study to date assessing the concordance of chromosome copy number between embryonic cell-free DNA and trophectoderm biopsy.


v1.2020

In a subgroup of 81 blastocysts, the comparison of the inner cell mass with the embryonic cell-free DNA and the trophoctoderm biopsies has shown similar concordance rates, 84.4% and 87.5% respectively.



The concordance rate was on average 78.2% ranging from 72.5% to 86.3% in different centers, without significant differences related to culture conditions or blastocyst quality.

## Two main objectives:




Embryonic cell-free DNA

### 1. Trophoctoderm DNA

To evaluate the concordance and reproducibility of testing embryonic cell-free DNA versus trophoctoderm DNA obtained from the same embryo in a large sample of 1,301 day 6 and day 7 human blastocysts.

### 2. Inner cell mass DNA

To assess the concordance rates between embryonic cell-free DNA, trophoctoderm DNA and the inner cell mass of the blastocyst in a subset of 81 aneuploid blastocysts donated for research.




## 4

**High concordance rates  
when comparing 1,301  
embryonic cell-free DNA and  
trophectoderm DNA samples**

The results of embryonic  
cell-free DNA from spent  
blastocyst media demonstrated  
a high concordance rate with  
the trophectoderm biopsy  
results.

	Center 1	Center 2	Center 3	Center 4	Center 5	Center 6	Center 7	Center 8	TOTAL
Concordance	75.6	77.1	81.8	86.3	84.2	85.0	72.5	77.0	<b>78.2</b>
Sensitivity	80.5	84.8	88.2	86.7	91.3	76.7	76.5	78.9	<b>81.7</b>
Specificity	69.9	72.7	85.2	87.5	80.0	93.3	64.7	78.1	<b>77.4</b>



We conclude that this non-invasive approach could avoid embryo biopsy, while making it accessible to a wider population of patients. **More studies are needed to understand the precise source of the embryonic cell-free DNA and the mechanisms involved.**



**[www.igenomix.ca](http://www.igenomix.ca)**  
+1 (514) 669-3869  
[infocanada@igenomix.com](mailto:infocanada@igenomix.com)